About Gamma-aminobutyric acid receptor subunit beta-1
Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1) is a protein
from Homo sapiens identified by UniProt accession
P18505, 474 residues long.
MolForge cross-references it against 0 known binders and
327 disease associations.
Target properties
| Protein name | Gamma-aminobutyric acid receptor subunit beta-1 |
| UniProt accession | P18505 |
| Gene | GABRB1 |
| Organism | Homo sapiens |
| Length | 474 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (327)
Diseases linked to this target (Open Targets).
- developmental and epileptic encephalopathy, 45 · score 0.68
- Seizure · score 0.61
- insomnia · score 0.61
- epilepsy · score 0.61
- migraine disorder · score 0.61
- pain · score 0.60
- alcohol dependence · score 0.60
- delirium · score 0.59
- obesity · score 0.58
- coronary artery disease · score 0.58
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P18505-F1 | alphafold | PREDICTED | 77.49 | — |
Amino-acid sequence (474 residues)
MWTVQNRESL GLLSFPVMIT MVCCAHSTNE PSNMSYVKET VDRLLKGYDI RLRPDFGGPP VDVGMRIDVA SIDMVSEVNM DYTLTMYFQQ SWKDKRLSYS GIPLNLTLDN RVADQLWVPD TYFLNDKKSF VHGVTVKNRM IRLHPDGTVL YGLRITTTAA CMMDLRRYPL DEQNCTLEIE SYGYTTDDIE FYWNGGEGAV TGVNKIELPQ FSIVDYKMVS KKVEFTTGAY PRLSLSFRLK RNIGYFILQT YMPSTLITIL SWVSFWINYD ASAARVALGI TTVLTMTTIS THLRETLPKI PYVKAIDIYL MGCFVFVFLA LLEYAFVNYI FFGKGPQKKG ASKQDQSANE KNKLEMNKVQ VDAHGNILLS TLEIRNETSG SEVLTSVSDP KATMYSYDSA SIQYRKPLSS REAYGRALDR HGVPSKGRIR RRASQLKVKI PDLTDVNSID KWSRMFFPIT FSLFNVVYWL YYVH
Explore Gamma-aminobutyric acid receptor subunit beta-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets